Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors

 Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors

PR Newswire

SEATTLE, Sept. 6, 2013

SEATTLE, Sept. 6, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
announced the appointment of Ted W. Love, M.D., to its board of directors.

"We are pleased  to welcome Dr.  Love, with his  extensive experience in  drug 
development, operations and corporate governance, to our board of  directors," 
said Robert  L.  Kirkman,  M.D.,  President and  Chief  Executive  Officer  of 
Oncothyreon.

Dr. Love  served  as  Executive  Vice  President  and  Head  of  Research  and 
Development and  Technical  Operations  at Onyx  Pharmaceuticals,  Inc.,  from 
February 2010 to August 2012.  From 2001 to January  2009, Dr. Love served  as 
Chairman and Chief Executive  Officer of Nuvelo, Inc.  Dr. Love joined  Nuvelo 
from Theravance, Inc., where he served as Senior Vice President of Development
from 1998 to 2001. Previously, he spent six years at Genentech, Inc., where he
held a number of  senior management positions in  medical affairs and  product 
development  and  served  as  chairman  of  Genentech's  Product   Development 
Committee. Dr. Love  also serves as  a member  of the boards  of directors  of 
biopharmaceutical companies Santarus, Inc.,  Amicus, Inc., and Kalobios,  Inc. 
Until April 2012, he served on the California Independent Citizens'  Oversight 
Committee. Dr. Love earned his Bachelor  of Science in molecular biology  from 
Haverford College and his M.D. from Yale Medical School.

About Oncothyreon

Oncothyreon is  a biotechnology  company specializing  in the  development  of 
innovative therapeutic  products for  the treatment  of cancer.  Oncothyreon's 
goal is to  develop and  commercialize novel synthetic  vaccines and  targeted 
small molecules that have the potential  to improve the lives and outcomes  of 
cancer patients. For more information, visit www.oncothyreon.com.

Additional Information

Additional information relating to Oncothyreon can be found on EDGAR at
www.sec.gov and on SEDAR at www.sedar.com.

SOURCE Oncothyreon Inc.

Contact:

Investor and Media Relations Contact:

Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
 
Press spacebar to pause and continue. Press esc to stop.